Results 221 to 230 of about 83,645 (265)
Some of the next articles are maybe not open access.
A live attenuated human rotavirus vaccine
Drugs of Today, 2007Rotavirus infections are the leading cause of severe gastroenteritis in young children worldwide. This review provides a summary of the development of a live oral rotavirus vaccine, Rotarix (GlaxoSmithKline, Rixensart, Belgium) developed from a single protective G1P[8] human strain.
openaire +2 more sources
Live, Attenuated Rubella-Virus Vaccine
New England Journal of Medicine, 1968HIGH priority is being given in the United States and Europe to the development of an effective live, attenuated rubella (German-measles) virus vaccine.
M R, Hilleman +3 more
openaire +2 more sources
Live Attenuated Varicella-Zoster Vaccine
Clinical Infectious Diseases, 1980Varicella-zoster (VZ) virus causes two diseases, varicella and zoster. Because it was recognized that, after varicella, latent VZ virus persisted in the host and because varicella was thought to be a milde disease, there was little impetus in North America to develop a live VZ vaccine.
openaire +2 more sources
Live Attenuated Oral Poliovirus Vaccine
Clinical Infectious Diseases, 1984During 1952-1954, some of the first papers were published on the attenuation of wild poliovirus for vaccine purposes. These efforts soon came to fruition , and large-scale field trials were held in many countries under a variety of conditions. Routine use of live oral poliovirus vaccines ( OPV ) was begun in many countries during the spring of 1960 ...
openaire +2 more sources
Live-attenuated chikungunya virus vaccine
CellAlthough Chikungunya fever does not a have a high fatality rate (
Lisa F P, Ng, Laurent, Rénia
openaire +2 more sources
Live, Attenuated Mumps-Virus Vaccine
New England Journal of Medicine, 1968Abstract Jeryl-Lynn strain (B level) live, attenuated mumps-virus vaccine was administered to 6283 initially susceptible children and 163 adults, including 132 males. There was no evident clinical reaction to the vaccine either in adults or in children including infants.
M R, Hilleman +3 more
openaire +2 more sources
Live Attenuated Vaccines for Pandemic Influenza
2009In this chapter, we will review the development of and clinical experience with the currently licensed seasonal live attenuated influenza vaccines (LAIV) and preclinical studies of H5, H7, and H9 live attenuated pandemic influenza vaccine candidates. Vectored vaccine approaches will not be reviewed in this chapter.
Grace L, Chen, Kanta, Subbarao
openaire +2 more sources
Live attenuated vaccines for human use
Current Opinion in Biotechnology, 1992Live attenuated vaccines have been successfully used for the prevention of a number of viral and bacterial diseases. Several vaccine strains have been utilized recently as expression vectors for cloned heterologous antigens. Through the use of recombinant DNA technology, candidate vaccine strains and vector systems have been developed and are ...
openaire +2 more sources
Live attenuated influenza vaccine for children
Drug and Therapeutics Bulletin, 2017For many years, the UK seasonal influenza vaccination programme has been offered to people at higher risk from the complications of influenza infection, including those aged over 65 years and anyone aged over 6 months who is in a clinical risk group.1 In 2012, the Joint Committee on Vaccination and Immunisation (JCVI) recommended extending seasonal ...
openaire +2 more sources
Generation of a live attenuated influenza A vaccine by proteolysis targeting
Nature Biotechnology, 2022Chengxin Zhang +2 more
exaly